FR06C0032I1 - - Google Patents
Info
- Publication number
- FR06C0032I1 FR06C0032I1 FR06C0032C FR06C0032I1 FR 06C0032 I1 FR06C0032 I1 FR 06C0032I1 FR 06C0032 C FR06C0032 C FR 06C0032C FR 06C0032 I1 FR06C0032 I1 FR 06C0032I1
- Authority
- FR
- France
- Prior art keywords
- pharmaceutical formulations
- osteoporosis
- useful
- concentration
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 abstract 1
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 102000058004 human PTH Human genes 0.000 abstract 1
- 239000008181 tonicity modifier Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to pharmaceutical formulations comprising human parathyroid hormone at a concentration from 0.3 to 10 mg/ml, a pharmaceutically acceptable buffer having a pH from 4 to 6, and at least one tonicity modifier. The said pharmaceutical formulations are useful for the treatment of bone related disorders such as osteoporosis.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9801495A SE9801495D0 (en) | 1998-04-28 | 1998-04-28 | Protein formulation |
| PCT/CA1999/000376 WO1999055353A2 (en) | 1998-04-28 | 1999-04-26 | Protein formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR06C0032I1 true FR06C0032I1 (en) | 2006-11-24 |
| FR06C0032I2 FR06C0032I2 (en) | 2007-04-27 |
Family
ID=20411122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR06C0032C Active FR06C0032I2 (en) | 1998-04-28 | 2006-10-20 | PROTEIN FORMULATIONS |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20050209144A1 (en) |
| EP (1) | EP1079803B1 (en) |
| JP (2) | JP4733267B2 (en) |
| KR (1) | KR100579872B1 (en) |
| CN (1) | CN1172658C (en) |
| AT (1) | ATE273693T1 (en) |
| AU (2) | AU766514B2 (en) |
| BR (1) | BR9909958A (en) |
| CA (1) | CA2329800C (en) |
| CY (1) | CY2006006I1 (en) |
| DE (3) | DE122006000057I2 (en) |
| DK (1) | DK1079803T3 (en) |
| ES (1) | ES2224637T3 (en) |
| FR (1) | FR06C0032I2 (en) |
| HK (1) | HK1041218B (en) |
| IL (1) | IL139320A (en) |
| LU (1) | LU91281I2 (en) |
| NL (1) | NL300243I2 (en) |
| NZ (1) | NZ508269A (en) |
| PT (1) | PT1079803E (en) |
| SE (1) | SE9801495D0 (en) |
| SI (1) | SI1079803T1 (en) |
| WO (1) | WO1999055353A2 (en) |
| ZA (1) | ZA200006040B (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6770623B1 (en) | 1997-12-09 | 2004-08-03 | Eli Lilly And Company | Stabilized teriparatide solutions |
| SE9801495D0 (en) * | 1998-04-28 | 1998-04-28 | Astra Ab | Protein formulation |
| WO2005014034A1 (en) * | 2003-07-14 | 2005-02-17 | Nps Allelix Corp. | Stabilized formulation of parathyroid hormone |
| CN101355959B (en) * | 2005-11-10 | 2013-02-27 | 密歇根理工大学管理委员会 | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
| SI2957278T1 (en) * | 2006-10-03 | 2017-09-29 | Radius Health, Inc. | A stable composition comprising pthrp and uses thereof |
| US7803770B2 (en) | 2006-10-03 | 2010-09-28 | Radius Health, Inc. | Method of treating osteoporosis comprising administration of PTHrP analog |
| USRE49444E1 (en) | 2006-10-03 | 2023-03-07 | Radius Health, Inc. | Method of treating osteoporosis comprising administration of PTHrP analog |
| FR2925333B1 (en) * | 2007-12-19 | 2012-04-13 | Farid Bennis | PHARMACEUTICAL COMPOSITIONS COMPRISING AT LEAST ONE PROTEIN ACTIVE INGREDIENT PROTECTS DIGESTIVE ENZYMES |
| JP2009091363A (en) * | 2008-11-21 | 2009-04-30 | Asahi Kasei Pharma Kk | Stabilized aqueous injectable solution of pth |
| EP2509996A1 (en) | 2009-12-07 | 2012-10-17 | Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
| ES2761635T3 (en) | 2011-06-07 | 2020-05-20 | Asahi Kasei Pharma Corp | Lyophilized preparation containing high purity PTH and method to produce it |
| CN103301058A (en) * | 2013-06-17 | 2013-09-18 | 深圳翰宇药业股份有限公司 | Composition for teriparatide injection, and preparation method and preparation thereof |
| PL3122426T3 (en) | 2014-03-28 | 2023-05-15 | Duke University | Treating breast cancer using selective estrogen receptor modulators |
| WO2016176665A1 (en) | 2015-04-29 | 2016-11-03 | Radius Health, Inc. | Methods of treating cancer |
| CN106309358A (en) * | 2015-06-29 | 2017-01-11 | 成都金凯生物技术有限公司 | Human parathyroid hormone-containing pharmaceutical composition and preparing method and use thereof |
| EP4374925A3 (en) | 2017-01-05 | 2025-01-15 | Radius Pharmaceuticals, Inc. | Polymorphic forms of rad1901-2hcl |
| CN108333360A (en) * | 2017-01-19 | 2018-07-27 | 深圳市新产业生物医学工程股份有限公司 | Gastrin-releasing peptide precursor dilution and its application and kit |
| US10996208B2 (en) | 2017-04-28 | 2021-05-04 | Radius Health, Inc. | Abaloparatide formulations and methods of testing, storing, modifying, and using same |
| JP6577683B2 (en) * | 2017-09-22 | 2019-09-18 | 旭化成ファーマ株式会社 | Liquid pharmaceutical composition containing teriparatide having excellent stability |
| CN108159404B (en) * | 2018-01-05 | 2019-08-27 | 北京博康健基因科技有限公司 | Recombinant human parathyroid hormone preparation and preparation method thereof |
| CN112423844B (en) | 2018-07-04 | 2024-08-13 | 雷迪厄斯制药公司 | Polymorphic forms of RAD1901-2HCL |
| CN119390714A (en) | 2019-02-12 | 2025-02-07 | 雷迪厄斯制药公司 | Methods and compounds |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5981485A (en) * | 1997-07-14 | 1999-11-09 | Genentech, Inc. | Human growth hormone aqueous formulation |
| US5744444A (en) * | 1989-10-27 | 1998-04-28 | Haemopep Pharma Gmbh | HPTH-fragment-(1-37), the preparation thereof, medicaments containing same and the use thereof |
| DE3935738A1 (en) * | 1989-10-27 | 1991-05-08 | Forssmann Wolf Georg | DRUGS CONTAINING THE HUMAN PARATHORMONE FRAGMENT (1-37) AS AN ACTIVE AGENT |
| US5547939A (en) * | 1991-06-14 | 1996-08-20 | The Regents Of The University Of California | Broad spectrum antimicrobial compounds and methods of use |
| US5563122A (en) * | 1991-12-09 | 1996-10-08 | Asahi Kasei Kogyo Kabushiki Kaisha | Stabilized parathyroid hormone composition |
| JP2662842B2 (en) * | 1991-12-09 | 1997-10-15 | 旭化成工業株式会社 | Parathyroid hormone stabilizing composition |
| NZ257212A (en) * | 1992-09-29 | 1996-11-26 | Inhale Therapeutic Syst | Parathyroid hormone formulations comprising a biologically active n-terminal fragment of the hormone |
| US5496801A (en) * | 1993-12-23 | 1996-03-05 | Allelix Biopharmaceuticals Inc. | Parathyroid hormone formulation |
| JPH09157294A (en) * | 1995-06-15 | 1997-06-17 | Takeda Chem Ind Ltd | Parathyroid hormone derivative |
| DE19538687A1 (en) * | 1995-10-17 | 1997-04-24 | Boehringer Mannheim Gmbh | Stable pharmaceutical dosage forms containing parathyroid hormone |
| JP4053107B2 (en) * | 1996-02-01 | 2008-02-27 | 中外製薬株式会社 | Preventive and therapeutic agents for thrombocytopenia |
| US5964807A (en) * | 1996-08-08 | 1999-10-12 | Trustees Of The University Of Pennsylvania | Compositions and methods for intervertebral disc reformation |
| DE19733651A1 (en) * | 1997-08-04 | 1999-02-18 | Boehringer Ingelheim Pharma | Aqueous aerosol preparations containing biologically active marrow molecules and processes for producing corresponding aerosols |
| SE9801495D0 (en) * | 1998-04-28 | 1998-04-28 | Astra Ab | Protein formulation |
-
1998
- 1998-04-28 SE SE9801495A patent/SE9801495D0/en unknown
-
1999
- 1999-04-26 SI SI9930678T patent/SI1079803T1/en unknown
- 1999-04-26 CA CA002329800A patent/CA2329800C/en not_active Expired - Lifetime
- 1999-04-26 EP EP99917715A patent/EP1079803B1/en not_active Expired - Lifetime
- 1999-04-26 DE DE122006000057C patent/DE122006000057I2/en active Active
- 1999-04-26 AT AT99917715T patent/ATE273693T1/en active
- 1999-04-26 NZ NZ508269A patent/NZ508269A/en not_active IP Right Cessation
- 1999-04-26 PT PT99917715T patent/PT1079803E/en unknown
- 1999-04-26 BR BR9909958-6A patent/BR9909958A/en not_active Application Discontinuation
- 1999-04-26 DE DE1999619533 patent/DE122006000057I1/en active Pending
- 1999-04-26 DE DE69919533T patent/DE69919533T2/en not_active Expired - Lifetime
- 1999-04-26 WO PCT/CA1999/000376 patent/WO1999055353A2/en not_active Ceased
- 1999-04-26 DK DK99917715T patent/DK1079803T3/en active
- 1999-04-26 HK HK02102980.6A patent/HK1041218B/en not_active IP Right Cessation
- 1999-04-26 AU AU35916/99A patent/AU766514B2/en not_active Expired
- 1999-04-26 KR KR1020007012037A patent/KR100579872B1/en not_active Expired - Lifetime
- 1999-04-26 JP JP2000545551A patent/JP4733267B2/en not_active Expired - Lifetime
- 1999-04-26 CN CNB998073628A patent/CN1172658C/en not_active Expired - Lifetime
- 1999-04-26 ES ES99917715T patent/ES2224637T3/en not_active Expired - Lifetime
- 1999-04-26 IL IL139320A patent/IL139320A/en not_active IP Right Cessation
-
2000
- 2000-10-26 ZA ZA200006040A patent/ZA200006040B/en unknown
-
2004
- 2004-01-16 AU AU2004200156A patent/AU2004200156B2/en not_active Expired
- 2004-11-30 US US10/999,160 patent/US20050209144A1/en not_active Abandoned
-
2006
- 2006-10-17 NL NL300243C patent/NL300243I2/en unknown
- 2006-10-19 LU LU91281C patent/LU91281I2/en unknown
- 2006-10-20 FR FR06C0032C patent/FR06C0032I2/en active Active
- 2006-10-23 CY CY200600006C patent/CY2006006I1/en unknown
-
2011
- 2011-01-24 JP JP2011011811A patent/JP5753692B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR06C0032I1 (en) | ||
| YU83502A (en) | New pharmaceutical composition | |
| BG104727A (en) | Pharmaceutical composition of topiramate | |
| BR0008059A (en) | Compositions of valdecoxib | |
| MY130727A (en) | Controlled-release pharmaceutical formulations | |
| AU2002225772A1 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
| PL309693A1 (en) | Combined osteoporosis inhibiting treatment | |
| ZA965235B (en) | Pharmaceutical and diet formulations for the prophylaxis and treatment of gastrointestinal disorders | |
| AP9801269A0 (en) | Prostaglandin agonists. | |
| MY118526A (en) | Method for improving the pharmacokinetics of tipranavir | |
| EP1420827B8 (en) | 5-cnac as oral delivery agent for parathyroid hormone fragments | |
| HUP0100024A3 (en) | Pharmaceutical compositions for treating alzheimer's disease containing carvedilol as active ingredient | |
| EP1032556A4 (en) | Pharmaceutically active compounds and methods of use | |
| BG102660A (en) | Combined pharmaceutical preparation of lhrh-analogues and antiesterogens for the treatment of gynaecological disorders | |
| BG104179A (en) | Phanquinon administration for the treatment of the alzheimer's disease | |
| UA66932C2 (en) | Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine | |
| IL164317A0 (en) | Statin therapy for enhancing cognitive maintenance | |
| GB9823515D0 (en) | Agent for the treatment of osteoporosis | |
| UA30798A (en) | Method of oncology patients prolonged therapy | |
| IT1307866B1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING INHIBITORS OF GROWTH HORMONE OR THEIR BIOLOGICALLY ACTIVE FRAGMENTS FOR TREATMENT | |
| MY118194A (en) | Pharmaceutical compositions for use in inhibiting bone resorption |